Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Breast Neoplasms 2Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Oligodendroglioma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioma 1Glioblastoma 1Disease 1Dermatofibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Astrocytoma 1

Interventions

Prednisone 3pembrolizumab 2Melphalan 2Cytarabine 2venetoclax 1ofatumumab 1obinutuzumab 1ioflupane 1imetelstat 1ibrutinib 1gossypol acetic acid 1gilteritinib 1fluorocholine 1fluciclovine F-18 1deltacortene 1daratumumab 1aflibercept 1abiraterone 1Temozolomide 1Self-Management 1Quality of Life 1Professional Autonomy 1Paclitaxel 1Oncolytic Virotherapy 1Octreotide 1Mitoxantrone 1Methylene Blue 1Lenalidomide 1Gemtuzumab 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Disease × Quality of Life × Clear all
NCT00712621 2009-11-24

Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination

American Scitech International

Phase 2 Withdrawn
460 enrolled
Breast

Breast Neoplasms, Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡